Related Experiment Video
Updated: Sep 2, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Nonalcoholic Fatty Liver Disease as a Risk Marker for Incident Type 2 Diabetes Mellitus: A Systematic Review
Mudathir Elyas Suleiman Khamees1, Egbal Abdalrahman Mohamed Ali2, Esra Bushra Hassan Babiker3
1Internal Medicine, Faculty of Medicine and Surgery, Alzaiem Alazhari University, Khartoum North, SDN.
Abstract:
Nonalcoholic fatty liver disease (NAFLD), now largely encompassed by the newer metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature, is increasingly recognized as a marker of systemic metabolic dysfunction. This systematic review synthesized longitudinal evidence from adults examining NAFLD and related steatotic liver disease definitions in relation to incident type 2 diabetes mellitus. PubMed/MEDLINE and Scopus were searched from inception, the supplementary search was repeated to capture recently published studies. Eligible longitudinal reports excluded participants with diabetes at baseline or clearly identified new-onset diabetes during follow-up. Because the included cohorts differed in liver disease definitions, diabetes ascertainment, populations, follow-up structures, and reported effect measures, the findings were synthesized narratively. The protocol was prepared before screening but was not prospectively registered. A total of 61 reports were included. Risk of bias was generally low to moderate where adequately assessed, while reports with incomplete domain-level information were interpreted cautiously. NAFLD or MASLD was generally associated with higher estimates of incident diabetes risk, although the magnitude varied and was attenuated after adjustment for metabolic factors in some studies. Persistent or newly developed steatosis and a greater liver fat or fibrosis burden were associated with higher estimates of future diabetes occurrence, whereas the resolution or reduction of liver fat was associated with lower estimates. Reported subgroup differences arose largely from individual or overlapping cohorts and were not sufficiently consistent to establish uniform effect modification. Overall, the evidence supports NAFLD or MASLD as a clinical risk marker rather than a stand-alone individualized prediction tool and supports standardized longitudinal assessments in future studies.
Related Concept Videos
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Diabetes: Symptoms, Diagnosis, and Complications